IBRX News

Pomerantz LLP Informs Shareholders of Class Action Against ImmunityBio, Inc. – IBRX

Pomerantz LLP Issues Reminder to Shareholders in ImmunityBio, Inc. of Class Action Filing – IBRX

ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff Deadline

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The Firm - IBRX

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

IBRX Lawsuit Alleges Misleading Cancer Claims - ImmunityBio Investors Face Losses Following $2B Market Cap Loss – Hagens Berman

Pomerantz LLP Notifies Investors of Class Action Against ImmunityBio, Inc. – IBRX